Log In Sign up
The largest database of trusted experimental protocols
> Living Beings > Bacterium > Streptococcus mutans

Streptococcus mutans

Streptococcus mutans is a Gram-positive bacterium and a major contributor to tooth decay.
It colonizes the human oral cavity and produces acids that demineralize tooth enamel, leading to the formation of dental caries.
S. mutans is a key target for researchers investigating preventive and therapeutic strategies against dental caries.
Profiling S. mutans virulence factors, metabolism, and interactions with the oral microbiome can inform the development of novel antimicrobial agents, vaccines, and treatment approaches to maintain oral health.
Optimizing research on this important oral pathogen is crucial for advancing our understanding and management of dental disease.

Most cited protocols related to «Streptococcus mutans»

1
Mock Community DNA Preparation
A single aliquot of the mock community was used throughout the sequencing effort analyzed in this study. This mock community represented 21 strains distributed among members of the Bacteria (n = 20) and Archaea (n = 1). Among the 20 bacterial sequences, there were 6 phyla, 10 classes, 12 orders, and 18 families and genera. The aliquot of mock community DNA was prepared by mixing genomic DNA from Acinetobacter baumanii (NC_009085), Actinomyces odontolyticus (DS264586), Bacillus cereus (AE017194), Bacteroides vulgatus (NC_009614), Clostridium beijerinckii (NC_009617), Deinococcus radiodurans (NC_001263), Enterococcus faecalis (NC_004668), Escherichia coli (NC_000913), Helicobacter pylori (NC_000915), Lactobacillus gasseri (NC_008530), Listeria monocytogenes (NC_003210), Neisseria meningitidis (NC_003112), Propionibacterium acnes (NC_006085), Pseudomonas aeruginosa (NC_002516), Rhodobacter sphaeroides (NC_007493, NC_007494), Staphylococcus aureus (NC_007793), Staphylococcus epidermidis (NC_004461), Streptococcus agalactiae (NC_004116), Streptococcus mutans (NC_004350), Streptococcus pneumoniae (NC_003028), and Methanobrevibacter smithii (NC_009515). Given the low homology between the three PCR primer pairs and the M. smithii 16S rRNA gene sequence, these sequences were rarely observed and have been omitted from the analysis of this study. The proportions of genomic DNAs added were calculated to have an equal number of 16S rRNA genes represented for each species; however, the original investigators did not verify the final relative abundances.
Schloss P.D., Gevers D, & Westcott S.L. (2011). Reducing the Effects of PCR Amplification and Sequencing Artifacts on 16S rRNA-Based Studies. PLoS ONE, 6(12), e27310.
Full text: Click here
Publication 2011
Acinetobacter Archaea Bacillus cereus Bacteria Bacteroides vulgatus Clostridium beijerinckii Deinococcus radiodurans DNA Enterococcus faecalis Escherichia coli Genes Genome Helicobacter pylori Lactobacillus gasseri Listeria monocytogenes Methanobrevibacter Neisseria meningitidis Oligonucleotide Primers Propionibacterium acnes Pseudomonas aeruginosa Rhodobacter sphaeroides Ribosomal RNA Genes RNA, Ribosomal, 16S Schaalia odontolytica Staphylococcus aureus Staphylococcus epidermidis Strains Streptococcus agalactiae Streptococcus mutans Streptococcus pneumoniae
2
Quantifying Cariogenic Biofilm Acid Production

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Acids Agar Bacitracin Bacteria Biofilms Blood Culture Cardiac Arrest Cysteine Enzymes Genetic Heterogeneity Gram-Positive Bacteria Lactate Dehydrogenase Lactates Lactic Acid Lacticaseibacillus casei Peptones potassium tellurite Streptococcus Streptococcus mutans Sucrose Trypan Blue Trypsin Violet, Gentian
3
Mock Community Microbiome Protocol
The organisms for the mock community (MC) include a variety of different genera commonly found on or within the human body. The MC composition has been described elsewhere [18] and additional data is available on the HMP Data Analysis and Coordination Center website (http://www.hmpdacc.org/). Genomic DNA from each organism was prepared individually and the DNAs were then mixed, based on 16S rRNA gene copy number, to create the MC. The organisms included were Acinetobacter baumannii ATCC 17978, Actinomyces odontolyticus ATCC 17982, Bacillus cereus ATCC 10987, Bacteroides vulgatus ATCC 8482, Clostridium beijerinckii ATCC 51743, Deinococcus radiodurans DSM 20539 (ATCC 13939), Enterococcus faecalis ATCC 47077, Escherichia coli ATCC 700926, Helicobacter pylori ATCC 700392, Lactobacillus gasseri DSM 20243 (ATCC 33323), Listeria monocytogenes ATCC BAA-679, Methanobrevibacter smithii ATCC 35061, Neisseria meningitidis ATCC BAA-335, Propionibacterium acnes DSM1 6379, Pseudomonas aeruginosa ATCC 47085, Rhodobacter sphaeroides ATCC 17023, Staphylococcus aureus ATCC BAA-1718, Staphylococcus epidermidis ATCC 12228, Streptococcus agalactiae ATCC BAA-611, Streptococcus mutans ATCC 700610, and Streptococcus pneumoniae ATCC BAA-334. Candida albicans ATCC MYA-2876 was included as a negative control but limited to only 1,000 18S copies (calculated) per µl.
Evaluation of 16S rDNA-Based Community Profiling for Human Microbiome Research. (2012). PLoS ONE, 7(6), e39315.
Full text: Click here
Publication 2012
Acinetobacter calcoaceticus Bacillus cereus Bacteroides vulgatus Candida albicans Clostridium beijerinckii Deinococcus radiodurans DNA Enterococcus faecalis Escherichia coli Genome Helicobacter pylori Human Body Lactobacillus gasseri Listeria monocytogenes Methanobrevibacter Neisseria meningitidis Propionibacterium acnes Pseudomonas aeruginosa Rhodobacter sphaeroides RNA, Ribosomal, 16S Schaalia odontolytica Staphylococcus aureus Staphylococcus epidermidis Streptococcus agalactiae Streptococcus mutans Streptococcus pneumoniae
4
Quantitative PCR for Total Bacterial Load
Total bacterial load was analyzed by quantitative PCR (7500 Fast Real-Time PCR system, Applied Biosystems, catalogue 4351107, Foster City, CA) using universal primers-probe set targeting the 16S rDNA gene, as described previously [6] (link). All samples were processed in quadruplicates.
CT values were related to the standard curve ranging from 0.1 pg/µl to 1 ng/µl of bacterial DNA. The reference DNA for the q-PCR standard curve was purified from 800 µl human saliva spiked with 104-bacteria of 6 orals strains, Streptococcus mutans, Fusobacterium nucleatum, Porphyromonas gingivalis, Porphyromonas catoniae, Propionibacterium propionicum, Tannerella forsythia. Total bacterial DNA was quantified by nanodrop and diluted to fit targeted concentrations. The reported qPCR results adhere to the MIQE standards for reporting qPCR data (Methods S2).
Biesbroek G., Sanders E.A., Roeselers G., Wang X., Caspers M.P., Trzciński K., Bogaert D, & Keijser B.J. (2012). Deep Sequencing Analyses of Low Density Microbial Communities: Working at the Boundary of Accurate Microbiota Detection. PLoS ONE, 7(3), e32942.
Full text: Click here
Publication 2012
Bacteria DNA, Bacterial DNA, Ribosomal Fusobacterium nucleatum Genes Homo sapiens Oligonucleotide Primers Porphyromonas catoniae Porphyromonas gingivalis Pseudopropionibacterium propionicum Saliva Strains Streptococcus mutans Tannerella forsythia
5
Biofilm Acid Production and Microorganism Viability

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Acids Agar Bacitracin Bacteria Biofilms Blood Culture Cysteine Enzymes Lactate Dehydrogenase Lactates Lactic Acid Neoplasm Metastasis Peptones Streptococcus Streptococcus mutans Sucrose Technique, Dilution Trypsin

Most recents protocols related to «Streptococcus mutans»

1
Antibacterial Dental Adhesives with Doped TiO2 NPs
Not available on PMC !

Example 4

The antibacterial efficacy of unaltered and experimental (doped) dental adhesive resins against non-disrupted cariogenic (caries producing) biofilms was further assessed in terms of relative luminescence units (RLUs) using a real-time luciferase-based bioluminescence assay. Toward this end, experimental dental adhesive resins containing either N—TiO2 NPs (5%-30%, v/v), N—F—TiO2 NPs (30%, v/v) and N—Ag—TiO2 NPs (30%, v/v) were synthesized by dispersing the nanoparticles in OBSP adhesive resin using a sonicator (4 cycles of 1 min, intervals of 15-sec between cycles; Q700, QSonica, USA). Two non-antibacterial (OBSP, and Scotchbond Multipurpose, 3M ESPE, USA) and one antibacterial (Clearfil SE Protect, Kuraray, Noritake Dental Inc., Japan) commercially available dental adhesive resins were also tested for antibacterial functionalities. Streptococcus mutans biofilms were grown (UA 159-ldh, JM 10; 37° C., microaerophilic) on the surfaces of disk-shaped specimens (n=18/group, d=6.0 mm, t=0.5 mm) for either 24 or 48 hours with or without continuous visible light irradiation (405±15 nm). One set of specimens was fabricated with OBSP and was treated with Chlorhexidine 2% (2 min) that served as our control group. Results for the antibacterial efficacies of both unaltered and experimental dental adhesive resins containing either doped or co-doped TiO2 NPs under continuous visible light irradiation for either 24 or 48 hours, demonstrated that all groups tested displayed similar antibacterial behaviors under continuous visible light irradiation. Such findings suggest that under the conditions investigated (wavelength and power intensity), visible light irradiation had a very strong antibacterial behavior that took place independently of the antibacterial activity of the substrate where biofilms were grown (either antibacterial or not). Such impact made impossible the determination of the materials' real antibacterial efficacies under such light irradiation conditions.

Experiments were then conducted under dark conditions; bacteria were grown in dark conditions for either 24 and 48 hours. The results indicated that the TiO2-containing adhesive resins were more antibacterial than commercially available non-antibacterial dental adhesive resins (such as OptiBond Solo Plus and Scotchbond Multipurpose). The experimental dental adhesive resins containing 30% (v/v) of nanoparticles (N—TiO2 NPs, N—F—TiO2 NPs and N—Ag—TiO2 NPs) displayed antibacterial efficacies in dark conditions that were similar to Clearfil SE Protect (Fluoride-releasing material, Kuraray, Noritake Dental Inc., Japan). S. mutans biofilms grown on specimens treated with chlorhexidine 2% (2 min) displayed the lowest RLU values amongst all groups investigated, thereby confirming the strong antibacterial behavior of non-immobilized chlorhexidine. In addition, the antibacterial effect was demonstrated to be concentration-dependent, wherein experimental adhesive resins containing higher concentrations of antibacterial nanoparticles (either doped or co-doped) displayed stronger antibacterial effects against non-disrupted S. mutans biofilms. Since long intra-oral irradiation periods (24-hour and 48-hour) are impractical and clinically not feasible, associated with the fact that these materials are intended to be used in the oral cavity's dark conditions, these results were considered of paramount importance and clinically relevant for the commercialization pathway of recently developed antibacterial and bioactive nano-filled dental adhesive resins.

Optical and mechanical properties of both unaltered and experimental dental adhesive resins containing 5%-30% (v/v, 5% increments) of N—TiO2 NPs were assessed in terms of color stability and biaxial flexure strength. Color stability (n=5) and biaxial flexure strength (n=8) specimens (d=6.0 mm, t=0.5 mm) were fabricated and tested using a color analysis software (ScanWhite, Darwin Syst., Brazil) and an Instron universal testing machine (cross-head rate=1.27 mm/min), respectively. Color stability measurements were performed immediately after specimen fabrication and after water storage (1, 2, 3, 4, 5, 6 months; 37° C.). The color stability results demonstrated that specimens fabricated using either unaltered or experimental dental adhesive resins containing N—TiO2 NPs (5%-30%, v/v) were subjected to color changes induced by long-term water storage. The highest color variations were observed at two months of water storage (37° C.) for specimens pertaining to experimental groups containing either 5% or 10% of N—TiO2 NPs. Specimens fabricated with unaltered OptiBond Solo Plus have demonstrated color variations that were similar to the color variations observed for the experimental group containing 20% N—TiO2 NPs. Specimens fabricated with 30% N—TiO2 NP-containing dental adhesive resins have shown the least amount of color variation throughout the investigation time (6-mo), and therefore, were considered as the most color stable amongst all materials investigated. From the esthetic standpoint, the human eye can only detect differences in color above a certain threshold (ΔE≥3).

In at least one embodiment, dental composition specimens fabricated with at 30% N—TiO2 NPs displayed color variations that were either lower than or close to the human eye detection capability, thereby corroborating the long-term use of these highly esthetic experimental dental adhesive resins. In at least certain embodiments, the dental compositions contain at least 5% to 80% (v/v) of doped-TiO2 NPs as disclosed herein, such as at least 5% (v/v), at least 6% (v/v), at least 7% (v/v), at least 8% (v/v), at least 9% (v/v), at least 10% (v/v), at least 11% (v/v), at least 12% (v/v), at least 13% (v/v), at least 14% (v/v), at least 15% (v/v), at least 16% (v/v), at least 17% (v/v), at least 18% (v/v), at least 19% (v/v), at least 20% (v/v), at least 21% (v/v), at least 22% (v/v), at least 23% (v/v), at least 24% (v/v), at least 25% (v/v), at least 26% (v/v), at least 27% (v/v), at least 28% (v/v), at least 29% (v/v), at least 30% (v/v), at least 31% (v/v), at least 32% (v/v), at least 33% (v/v), at least 34% (v/v), at least 35% (v/v), at least 36% (v/v), at least 37% (v/v), at least 38% (v/v), at least 39% (v/v), at least 40% (v/v), at least 41% (v/v), at least 42% (v/v), at least 43% (v/v), at least 44% (v/v), at least 45% (v/v), at least 46% (v/v), at least 47% (v/v), at least 48% (v/v), at least 49% (v/v), at least 50% (v/v), at least 51% (v/v), at least 52% (v/v), at least 53% (v/v), at least 54% (v/v), at least 55% (v/v), at least 56% (v/v), at least 57% (v/v), at least 58% (v/v), at least 59% (v/v), at least 60% (v/v), at least 61% (v/v), at least 62% (v/v), at least 63% (v/v), at least 64% (v/v), at least 65% (v/v), at least 66% (v/v), at least 67% (v/v), at least 68% (v/v), at least 69% (v/v), at least 70% (v/v), at least 71% (v/v), at least 72% (v/v), at least 73% (v/v), at least 74% (v/v), at least 75% (v/v), at least 76% (v/v), at least 77% (v/v), at least 78% (v/v), at least 79% (v/v), or at least 80% (v/v), with the balance comprising the curable adhesive resin material, and optionally other components as described elsewhere herein.

The present results demonstrate that experimental dental adhesive resins containing varying concentrations of N—TiO2 NPs display biaxial flexure strengths that are either similar or better than the strength observed for specimens fabricated with the unaltered OBSP. No differences were observed among the flexure strengths of experimental groups, thereby indicating that the presently disclosed materials can behave very similar to commercially available materials when subjected to masticatory forces.

Specimens (d=6.0 mm, t=0.5 mm) of the unaltered resins and experimental dental adhesive resins containing 30% N—TiO2 NPs, 30% N—F—TiO2 NPs and 30% N—Ag—TiO2 NPs were fabricated and characterized using the state of the art scanning electron microscope. This dual focused ion-beam microscope (Dual-FIB SEM/EDS) is capable, through a destructive process, to characterize and map the chemical composition and distribution of elements in three dimensions. The 3-D characterization and localization of components clearly demonstrated that experimental materials containing co-doped nanoparticles (e.g., 30% v/v, N—F—TiO2 NPs) displayed an optimized dispersion of filler particles (part of the original composition) when compared to the filler particle distribution observed on specimens fabricated with the unaltered dental adhesive resin. The 3-D images demonstrated that the experimental adhesive resins had more filler particles per unit volume with a more homogeneous size distribution than the filler fraction and size distribution observed on OptiBond Solo Plus samples. In addition, results showed that larger and more agglomerated filler particles tend to result in a polymer matrix containing more pores per unit volume. This finding was corroborated by the pore-size distribution calculated for the unaltered samples and experimental dental adhesive resin samples, where it is possible to observe that the quantity and sizes of pores formed in experimental materials were smaller when compared to the unaltered OptiBond Solo Plus samples.

In at least one embodiment, the present disclosure includes a dental composition, comprising doped and/or coated TiO2 NPs, and a curable resin material, wherein the curable resin material comprises a polymer precursor component. The TiO2 NPs may comprise at least one dopant or coating selected from the group consisting of N (nitrogen), Ag (silver), F (fluorine), P (phosphorus), and PO4 (phosphate). As noted above, in non-limiting embodiments, the dental composition may comprise a volume to volume ratio of doped TiO2 NPs to curable resin material in a range of 1% to 80% (v/v), 5% to 50% (v/v), or 10% to 40% (v/v), for example. The polymer precursor component may be photocurable. The polymer precursor may be selected from the group consisting of acrylates, methacrylates, dimethacrylates, epoxies, vinyls and thiols. The polymer precursor may be selected from the group consisting of ethylenedimethacrylate (“EDMA”), bisphenol A glycidyl methacrylate (“BisGMA”), triethyleneglycol dimethacrylate (“TEGDMA”), 1,6-bis(methacryloxy-2-ethoxycarbonylamino)-2,4,4-trimethylhexane (UDMA), pyromellitic glycerol dimethacrylate (PMGDM), and 2-hydroxyethyl methacrylate (HEMA). The dental composition may comprise at least one solvent. The at least one solvent may be selected from the group consisting of water, ethanol, methanol, toluene, ethyl ether, cyclohexane, isopropanol, chloroform, ethyl acetate, acetone, hexane, and heptanes. The dental composition may comprise a polymerization initiator. The dental composition may comprise a filler. The dental composition may be selected from the group consisting of dental resins, dental bonding agents, dental adhesives, dental cements, dental restoratives, dentals coatings, dental sealants, acrylic resins, and denture teeth. The dental composition may comprise bioactive and/or antibacterial activity in the absence of visible or ultraviolet light. The dental composition may be used to form a hardened dental article after a photocuring step. In at least one embodiment, the disclosure includes an in vivo dental process, comprising applying the dental composition to at least one of a dental restorative and a dental substrate, and causing the dental restorative to be bonded to the dental substrate via the dental composition after a step of photocuring the dental composition.

Accordingly, the present disclosure is directed to at least the following non-limiting embodiments:

Clause 1. In at least one embodiment the present disclosure includes a dental composition, comprising doped TiO2 nanoparticles, and a curable resin material, wherein the curable resin material comprises a polymer precursor component.

Clause 2. The dental composition of clause 1, wherein the doped TiO2 nanoparticles comprise at least one dopant selected from the group consisting of N (nitrogen), Ag (silver), F (fluorine), P (phosphorus), and PO4 (phosphate).

Clause 3. The dental composition of clause 1 or 2, wherein the doped TiO2 nanoparticles further comprise at least one second dopant selected from the group consisting of N, Ag, F, P, and PO4.

Clause 4. The dental composition of any one of clauses 1-3, comprising a volume to volume ratio of doped TiO2 nanoparticles to curable resin material in a range of 1% to 80% (v/v).

Clause 5. The dental composition of any one of clauses 1-4, comprising a volume to volume ratio of doped TiO2 nanoparticles to curable resin material in a range of 5% to 50% (v/v).

Clause 6. The dental composition of any one of clauses 1-5, comprising a volume to volume ratio of doped TiO2 nanoparticles to curable resin material in a range of 10% to 40% (v/v).

Clause 7. The dental composition of any one of clauses 1-6, wherein the polymer precursor component is photocurable.

Clause 8. The dental composition of any one of clauses 1-7, wherein the polymer precursor is selected from the group consisting of acrylates, methacrylates, dimethacrylates, epoxies, vinyls and thiols.

Clause 9. The dental composition of any one of clauses 1-8, wherein the polymer precursor is at least one selected from the group consisting of ethylenedimethacrylate (EDMA), bisphenol A glycidyl methacrylate (BisGMA), triethyleneglycol dimethacrylate (TEGDMA), 1,6-bis(methacryloxy-2-ethoxycarbonylamino)-2,4,4-trimethylhexane (UDMA), pyromellitic glycerol dimethacrylate (PMGDM), and 2-hydroxyethyl methacrylate (HEMA).

Clause 10. The dental composition of any one of clauses 1-9, further comprising at least one solvent.

Clause 11. The dental composition of any one of clauses 1-10, further comprising a solvent selected from the group consisting of water, ethanol, methanol, acetone, toluene, ethyl ether, cyclohexane, isopropanol, chloroform, ethyl acetate, hexane, and heptanes.

Clause 12. The dental composition of any one of clauses 1-11, further comprising a polymerization initiator.

Clause 13. The dental composition of any one of clauses 1-12, further comprising a filler.

Clause 14. The dental composition of any one of clauses 1-13, wherein the curable resin material is selected from the group consisting of dental resins, dental bonding agents, dental adhesives, dental cements, dental restoratives, dentals coatings, dental sealants, acrylic resins, and denture teeth.

Clause 15. The dental composition of any one of clauses 1-14, comprising bioactive and/or antibacterial activity in the absence of visible or ultraviolet light.

Clause 16. A kit for forming a dental composition, the kit comprising doped TiO2 nanoparticles, and a curable resin material, wherein the curable resin material comprises a polymer precursor component.

Clause 17. The kit of clause 16, wherein the doped TiO2 nanoparticles comprise at least one dopant selected from the group consisting of N (nitrogen), Ag (silver), F (fluorine), P (phosphorus), and PO4 (phosphate).

Clause 18. The kit of clause 16 or 17, wherein the doped TiO2 nanoparticles further comprise at least one second dopant selected from the group consisting of N, Ag, F, P, and PO4.

Clause 19. The kit of any one of clauses 16-18, comprising sufficient doped TiO2 nanoparticles and curable resin material such that the dental composition comprises a volume to volume ratio of doped TiO2 nanoparticles to curable resin material in a range of 1% to 80% (v/v).

Clause 20. The kit of any one of clauses 16-19, comprising sufficient doped TiO2 nanoparticles and curable resin material such that the dental composition comprises a volume to volume ratio of doped TiO2 nanoparticles to curable resin material in a range of 5% to 50% (v/v).

Clause 21. The kit of any one of clauses 16-20, comprising sufficient doped TiO2 nanoparticles and curable resin material such that the dental composition comprises a volume to volume ratio of doped TiO2 nanoparticles to curable resin material in a range of 10% to 40% (v/v).

Clause 22. The kit of any one of clauses 16-21, wherein the polymer precursor component is photocurable.

Clause 23. The kit of any one of clauses 16-22, wherein the polymer precursor is selected from the group consisting of acrylates, methacrylates, dimethacrylates, epoxies, vinyls and thiols.

Clause 24. The kit of any one of clauses 16-23, wherein the polymer precursor is at least one selected from the group consisting of ethylenedimethacrylate (EDMA), bisphenol A glycidyl methacrylate (BisGMA), triethyleneglycol dimethacrylate (TEGDMA), 1,6-bis(methacryloxy-2-ethoxycarbonylamino)-2,4,4-trimethylhexane (UDMA), pyromellitic glycerol dimethacrylate (PMGDM), and 2-hydroxyethyl methacrylate (HEMA).

Clause 25. The kit of any one of clauses 16-24, further comprising at least one solvent.

Clause 26. The kit of any one of clauses 16-25, further comprising a solvent selected from the group consisting of water, ethanol, methanol, acetone, toluene, ethyl ether, cyclohexane, isopropanol, chloroform, ethyl acetate, hexane, and heptanes.

Clause 27. The kit of any one of clauses 16-26, further comprising a polymerization initiator for combining with the doped TiO2 nanoparticles, and curable resin material.

Clause 28. The kit of any one of clauses 16-27, further comprising a filler for combining with the doped TiO2 nanoparticles, and curable resin material.

Clause 29. The kit of any one of clauses 16-28, wherein the curable resin material is selected from the group consisting of dental resins, dental bonding agents, dental adhesives, dental cements, dental restoratives, dentals coatings, dental sealants, acrylic resins, and denture teeth.

Clause 30. The kit of any one of clauses 16-29, wherein the dental composition has bioactive and/or antibacterial activity in the absence of visible or ultraviolet light.

Clause 31. A hardened dental article formed from the dental composition of any one of clauses 1-15, after the dental composition has been photocured.

Clause 32. An in vivo dental process, comprising: applying a dental composition to a dental surface, the dental composition comprising doped TiO2 nanoparticles, and a curable resin material, wherein the curable resin material comprises a polymer precursor component; and causing the dental composition to be bonded to the dental surface by photocuring the dental composition.

Clause 33. The dental process of clause 32, wherein the dental surface is at least one of a dental restorative and a dental substrate.

Clause 34. The dental process of clause 32 or 33, wherein the doped TiO2 nanoparticles comprise at least one dopant selected from the group consisting of N (nitrogen), Ag (silver), F (fluorine), P (phosphorus), and PO4 (phosphate).

Clause 35. The dental process of any one of clauses 32-34, wherein the doped TiO2 nanoparticles further comprise at least one second dopant selected from the group consisting of N, Ag, F, P, and PO4.

Clause 36. The dental process of any one of clauses 32-35, wherein the dental composition comprises a volume to volume ratio of doped TiO2 nanoparticles to curable resin material in a range of 1% to 80% (v/v).

Clause 37. The dental process of any one of clauses 32-36, wherein the dental composition comprises a volume to volume ratio of doped TiO2 nanoparticles to curable resin material in a range of 5% to 50% (v/v).

Clause 38. The dental process of any one of clauses 32-37, wherein the dental composition comprises a volume to volume ratio of doped TiO2 nanoparticles to curable resin material in a range of 10% to 40% (v/v).

Clause 39. The dental process of any one of clauses 32-38, wherein the polymer precursor component is photocurable.

Clause 40. The dental process of any one of clauses 32-39, wherein the polymer precursor is selected from the group consisting of acrylates, methacrylates, dimethacrylates, epoxies, vinyls and thiols.

Clause 41. The dental process of any one of clauses 32-40, wherein the polymer precursor is at least one selected from the group consisting of ethylenedimethacrylate (EDMA), bisphenol A glycidyl methacrylate (BisGMA), triethyleneglycol dimethacrylate (TEGDMA), 1,6-bis(methacryloxy-2-ethoxycarbonylamino)-2,4,4-trimethylhexane (UDMA), pyromellitic glycerol dimethacrylate (PMGDM), and 2-hydroxyethyl methacrylate (HEMA).

Clause 42. The dental process of any one of clauses 32-41, wherein the dental composition further comprises at least one solvent.

Clause 43. The dental process of any one of clauses 32-42, further comprising a solvent selected from the group consisting of water, ethanol, methanol, acetone, toluene, ethyl ether, cyclohexane, isopropanol, chloroform, ethyl acetate, hexane, and heptanes.

Clause 44. The dental process of any one of clauses 32-43, wherein the dental composition further comprises a polymerization initiator.

Clause 45. The dental process of any one of clauses 32-44, wherein the dental composition further comprises a filler.

Clause 46. The dental process of any one of clauses 32-45, wherein the curable resin material is selected from the group consisting of dental resins, dental bonding agents, dental adhesives, dental cements, dental restoratives, dentals coatings, dental sealants, acrylic resins, and denture teeth.

Clause 47. The dental process of any one of clauses 32-46, wherein after curing, the dental composition has bioactive and/or antibacterial activity in the absence of visible or ultraviolet light.

Clause 48. The dental process of any one of clauses 32-47, wherein the dental surface has been acid-etched prior to the application of the dental composition thereon.

While the present disclosure has been described herein in connection with certain embodiments so that aspects thereof may be more fully understood and appreciated, it is not intended that the present disclosure be limited to these particular embodiments. On the contrary, it is intended that all alternatives, modifications and equivalents are included within the scope of the present disclosure as defined herein. Thus the examples described above, which include particular embodiments, will serve to illustrate the practice of the inventive concepts of the present disclosure, it being understood that the particulars shown are by way of example and for purposes of illustrative discussion of particular embodiments only and are presented in the cause of providing what is believed to be the most useful and readily understood description of procedures as well as of the principles and conceptual aspects of the present disclosure. Changes may be made in the formulation of the various compositions described herein, the methods described herein or in the steps or the sequence of steps of the methods described herein without departing from the spirit and scope of the present disclosure. Further, while various embodiments of the present disclosure have been described in claims herein below, it is not intended that the present disclosure be limited to these particular claims.

US11857651B2. Compositions with doped titanium dioxide nanoparticles and methods of use (2024-01-02). The Board of Regents of the University of Oklahoma [US]. Inventors: Fernando Luis Esteban Florez [US], Sharukh Soli Khajotia [US], Adam Justin Rondinone [US].
Full text: Click here
Patent 2024
2-hydroxyethyl methacrylate Acetone Acids Acrylates Acrylic Resins Anti-Bacterial Agents Bacteria Biofilms Bioluminescent Measurements Bisphenol A-Glycidyl Methacrylate chemical composition Chlorhexidine Chloroform Cyclohexane Dental Caries Dental Cements Dental Resins Dentures Epoxy Resins Ethanol ethyl acetate Ethyl Ether Fluorides Fluorine Focused Ion Beam Scanning Electron Microscopy Glycerin Head Heptanes Hexanes Homo sapiens Isopropyl Alcohol JM 10 Light Light, Visible Luciferases Luminescence Methacrylates Methanol Microscopy Mouth Diseases Nitrogen OptiBond SOLO Phosphates Phosphorus Pit and Fissure Sealants Polymerization Polymers Polyvinyl Chloride Radiotherapy Resins, Plant Scanning Electron Microscopy Sclerosis Scotchbond Silver Solvents Streptococcus mutans Sulfhydryl Compounds T.E.R.M. composite resin titanium dioxide Toluene Tooth triethylene glycoldimethacrylate Ultraviolet Rays Vision
2
Bacterial Species Identification via SERS Spectra
To identify different types of bacterial species from the collected
SERS spectra, we used the common machine learning algorithms from
the open-source Python (3.8) library, Scikit-learn. To read, process,
and visualize the spectral data, we used python packages: NumPy, SciPy,
Matplotlib, and Seaborn.
To classify the five different bacteria
species, 1114 SERS spectra were recorded on the Ag–CuxO nanostructures. These include 157 for Bacillus subtilis (B. subtilis), 309 for Escherichia coli (E. coli), 155 for Enterococcus faecalis (E. faecalis), 343 for Staphylococcus aureus (S. aureus), and 150 for Streptococcus mutans (S. mutans). Specifically, the data
were first normalized using StandardScaler and then principal component
analysis (PCA) was applied on the transformed data. Machine learning
methods were used to distinguish bacteria. To facilitate the machine
learning-based identification for real-life adaptation, the spectral
data obtained from bacteria were used directly, without any pre-processing
such as background subtraction or smoothing. For each bacterial species,
approximately 66.7% of the spectral data were used as training data,
which was obtained by parsing it using the randomization parameter
(randomization coefficient = 40) of the split function from the Scikit-learn
library. These data were used to train classification algorithms like
support vector machines (SVM), k-nearest neighbors (KNN), and decision
tree. Finally, the remaining approximately 33.3% of the bacterial
spectra were used to test the accuracy of the system.
Sahin F., Camdal A., Demirel Sahin G., Ceylan A., Ruzi M, & Onses M.S. (2023). Disintegration and Machine-Learning-Assisted Identification of Bacteria on Antimicrobial and Plasmonic Ag–CuxO Nanostructures. ACS Applied Materials & Interfaces, 15(9), 11563-11574.
Full text: Click here
Publication 2023
Acclimatization Bacillus subtilis Bacteria Bacterial Typing Cloning Vectors DNA Library Enterococcus faecalis Escherichia coli Python Staphylococcus aureus Streptococcus mutans
3
Streptococcus mutans Acquisition in Twins
Parents/carers collected the initial samples from the twins by following detailed instructions given in Fig. S8. The samples were cultured within 7–10 days of reception to check for Streptococcus mutans. This was undertaken to check viability of the samples collected by the parents/carers.
Samples were plated on agar selective for Streptococcus mutans (TSYC20B) which was incubated for 72 h at 37 °C in an atmosphere of 95% nitrogen and 5% carbon dioxide. Following incubation S mutans was identified by characteristic colony morphology under a dissecting microscope. A sub-sample of positive colonies was confirmed by carbohydrate fermentation patterns. Each sample was assessed independently. After three contiguous positive cultures for S mutans it was assumed that S mutans had been acquired. The samples were then placed in black semi-solid transport media VMG II50 (link) and stored at 80 °C.
Sukumar S., Wang F., Simpson C.A., Willet C.E., Chew T., Hughes T.E., Bockmann M.R., Sadsad R., Martin F.E., Lydecker H.W., Browne G.V., Davis K.M., Bui M., Martinez E, & Adler C.J. (2023). Development of the oral resistome during the first decade of life. Nature Communications, 14, 1291.
Full text: Click here
Publication 2023
Agar Atmosphere Carbohydrates Carbon dioxide Fermentation Microscopy Nitrogen Parent Streptococcus mutans Twins
4
Biofilm Formation Protocols for Clinically Relevant Microbes
The biofilms were developed on 96-well flat-bottomed polystyrene microtitre plates (Eppendorf, Hamburg, Germany) by using different media and growth conditions depending on the species. The OD600 of each inoculum was read and adjusted to reach a final concentration in each well of 1.0 × 105 CFU/mL. More details are given as follows:

Escherichia coli ATCC 25922 was grown in Mueller Hinton Broth (MHB; Oxoid Limited, Hampshire, United Kingdom), and the biofilm was developed in MHB for 24 h of incubation at 37°C in static and aerobic conditions;

Pseudomonas aeruginosa ATCC 27853 growth and biofilm formation were conducted in Luria Bertani Broth (LB; Oxoid Limited, Hampshire, United Kingdom) for 24 h of incubation at 37°C in static and aerobic conditions;

Streptococcus mutans UA 159 was grown in Brain Heart Infusion (BHI; Oxoid Limited, Hampshire, United Kingdom), and the biofilm was developed in BHI + 1% of sucrose (BHIS) for 24 h of incubation at 37°C in static and anaerobic conditions;

Staphylococcus aureus ATCC 29213 was grown in Tryptic Soy Broth (TSB; Oxoid Limited, Hampshire, United Kingdom), and the biofilm was developed in TSB + 1% of glucose (TSBG) for 24 h of incubation at 37°C in static and aerobic conditions;

Fusobacterium nucleatum ATCC 25586 growth and biofilm formation were conducted in BHI for 48 h of incubation at 37°C in static and anaerobic conditions.

Vitale I., Spano M., Puca V., Carradori S., Cesa S., Marinacci B., Sisto F., Roos S., Grompone G, & Grande R. (2023). Antibiofilm activity and NMR-based metabolomic characterization of cell-free supernatant of Limosilactobacillus reuteri DSM 17938. Frontiers in Microbiology, 14, 1128275.
Full text: Click here
Publication 2023
Bacteria, Aerobic Biofilms Brain Escherichia coli Fusobacterium nucleatum Glucose Growth Disorders Heart Polystyrenes Pseudomonas aeruginosa Staphylococcus aureus Streptococcus mutans Sucrose tryptic soy broth
5
Quantification of Bacterial Adherence
Bacterial analysis was carried out using Streptococcus mutans (S. mutans) (KCOM 3478) cultured in Brain Heart Infusion (BHI) broth (Difco, Sparks, MD, USA) with 2% sucrose added, and incubated at 37 °C for 18 h under aerobic condition. The samples for the bacterial experiment were manufactured in disc-shaped (10 mm × 2 mm) and sterilized in ethylene oxide gas. Then, 1 mL of the cultured bacterial suspension (1 × 108 cells/mL) was placed into the specimens in a 24-well plate and incubated for 18 h. To remove the non-adherent bacteria, the samples were gently washed twice with distilled water. Afterward, the samples were sonicated (SH-2100; Saehan Ultrasonic, Seoul, Korea) for 5 min while immersed in distilled water for measuring the optical density (OD) values. The bacterial solution thus obtained after sonication was seeded (100 μL) in a 96-well plate and OD values (450 nm) were measured using a microplate reader (Epoch, BioTek Instruments, VT, USA)25 (link).
Wu C., Kim M.J., Mangal U., Seo J.Y., Kim J.Y., Kim J., Park J.Y., Kwon J.S, & Choi S.H. (2023). Effect of bacterial resistant zwitterionic derivative incorporation on the physical properties of resin-modified glass ionomer luting cement. Scientific Reports, 13, 3589.
Full text: Click here
Publication 2023
Bacteria Bacteria, Aerobic Brain Cells EPOCH protocol Hartnup Disease Heart Oxide, Ethylene Streptococcus mutans Sucrose Ultrasonics Vision

Top products related to «Streptococcus mutans»

1
Streptococcus mutans by American Type Culture Collection
Sourced in United States
Streptococcus mutans is a species of bacteria commonly found in the human oral cavity. It is a Gram-positive, coccus-shaped bacterium that is known for its ability to produce lactic acid, which can contribute to the development of dental cavities. This lab equipment product provides a pure culture of Streptococcus mutans for research and study purposes.
2
Staphylococcus aureus by American Type Culture Collection
Sourced in United States, China, United Kingdom, Germany, Brazil, Malaysia, Italy, Portugal
Staphylococcus aureus is a bacterial strain available in the American Type Culture Collection (ATCC) product portfolio. It is a Gram-positive, spherical-shaped bacterium commonly found in the human nasal passages and on the skin. This strain is widely used in research and laboratory settings for various applications.
3
Escherichia coli by American Type Culture Collection
Sourced in United States, China, Germany, United Kingdom, France, Portugal, Canada, Brazil, Italy
Escherichia coli is a bacterium that is commonly used in laboratory settings. It serves as a model organism for microbiology and molecular biology research. Escherichia coli can be cultivated and studied to understand fundamental cellular processes and mechanisms.
4
Bhi broth by BD
Sourced in United States, France, Japan
BHI broth is a general-purpose microbiological growth medium. It is composed of a mixture of nutrients designed to support the growth of a wide range of microorganisms, including bacteria, yeast, and fungi. The broth provides essential nutrients and growth factors required for microbial proliferation.
5
Pseudomonas aeruginosa by American Type Culture Collection
Sourced in United States, Brazil, China, Germany, Australia, United Kingdom, Italy, Malaysia
Pseudomonas aeruginosa is a bacterial strain available from the American Type Culture Collection (ATCC). It is a Gram-negative, aerobic bacterium commonly found in soil and water environments. This strain can be used for various research and testing purposes.
6
Candida albicans by American Type Culture Collection
Sourced in United States, Australia, Germany, Italy, France
Candida albicans is a species of yeast that is commonly found in the human microbiome. It is a versatile and well-studied organism used in a variety of laboratory applications, including microbiology, immunology, and biochemistry research.
7
Staphylococcus epidermidis by American Type Culture Collection
Sourced in United States, United Kingdom, China
Staphylococcus epidermidis is a type of bacteria commonly found on the human skin and mucous membranes. It is a Gram-positive, coagulase-negative, and non-spore-forming coccus. Staphylococcus epidermidis is a prevalent microorganism and is often used in research and laboratory settings for various applications.
8
Enterococcus faecalis by American Type Culture Collection
Sourced in United States, Germany, Malaysia
Enterococcus faecalis is a Gram-positive, facultatively anaerobic bacterium. It is commonly found in the human gastrointestinal tract and is known for its ability to survive in diverse environments.
9
Bacillus subtilis by American Type Culture Collection
Sourced in United States, China, Brazil
Bacillus subtilis is a Gram-positive, rod-shaped bacterium commonly found in soil and the gastrointestinal tract of humans and animals. It is a widely used laboratory strain for research and industrial applications.
10
Bacillus cereus by American Type Culture Collection
Sourced in United States, Portugal, China
Bacillus cereus is a Gram-positive, spore-forming bacterium that is commonly found in the environment. It is a type of microorganism that can be used in various laboratory applications.

More about "Streptococcus mutans"

Streptococcus mutans, a gram-positive oral bacterium, is a primary culprit in the development of tooth decay and dental caries.
This opportunistic pathogen colonizes the human oral cavity, producing acidic byproducts that erode tooth enamel.
S. mutans is a key target for researchers investigating preventive and therapeutic strategies to maintain oral health and manage dental disease.
Profiling the virulence factors, metabolism, and microbial interactions of S. mutans is crucial for advancing our understanding of this important oral pathogen.
Researchers are exploring novel antimicrobial agents, vaccines, and treatment approaches to combat S. mutans and related oral bacteria like Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
The use of growth media like Brain Heart Infusion (BHI) broth can support the cultivation and study of S. mutans, as well as other oral microbes such as Candida albicans, Staphylococcus epidermidis, Enterococcus faecalis, Bacillus subtilis, and Bacillus cereus.
By optimizing research methods and protocols, scientists can gain valuable insights into the complex oral microbiome and develop innovative strategies to maintain dental health and prevent cariese.